Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia(ALL) with a 100% Response Rate!
Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia with a 100% Response Rate!
ALL
In recent years, CAR-T cell therapies from China have garnered global attention in the fight against cancer, and now another CAR-T product is about to hit the market. Priscabtagene Autoleucel Injection (pCAR-19B), developed by China’s Precision Biotech, is specifically designed for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and is currently under priority review for approval. It is poised to become China’s first CAR-T therapy specifically tailored for children and adolescents with acute leukemia.
This groundbreaking therapy has shown remarkable efficacy, achieving a 100% overall response rate in early clinical trials. For patients who no longer respond to conventional treatments, Priscabtagene Autoleucel offers a new lifeline. The therapy has demonstrated superior safety and efficacy in clinical settings, thanks to gene optimization and advanced vector systems that reduce side effects while enhancing effectiveness.
Currently, pCAR-19B has entered Phase II clinical trials, expanding its scope beyond children to include adult patients with relapsed leukemia. It is also being researched for the treatment of other malignant lymphomas, such as diffuse large B-cell lymphoma and follicular lymphoma. This signifies the vast potential of CAR-T therapies in China, promising more effective treatment options for blood cancer patients both domestically and globally.
Precision Biotech’s CAR-T therapy is expected to gain approval soon, contributing to global medical innovation while bringing new hope to countless patients.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
What Types of Lymphoma Patients Are Suitable for CAR-T Treatment in China？
# What Types of Lymphoma Patients Are Suitable for CAR-T Treatment in China?
Lymphoma
#CART #Lymphoma #DLBCL #LBCL #MedicalTourism #FL #MCL
In recent years, CAR-T cell therapy has sparked a revolution in cancer treatment worldwide, achieving remarkable results, especially in lymphoma care. As one of the global leaders in CAR-T therapy, China has attracted a large number of international patients seeking this cutting-edge immunotherapy. So, what types of lymphoma patients are suitable to travel to China for this advanced treatment?
## Indications: The First Choice for Relapsed or Refractory Lymphoma Patients
CAR-T treatment in China primarily targets patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). Specific patient groups that are suitable include:
1. **Relapsed DLBCL**: Patients who did not respond to first-line treatments, such as R-CHOP, or relapsed within 12 months after treatment.
2. **Follicular Lymphoma (FL)**: Patients with grade 1-3a FL who have relapsed or are refractory after at least two lines of treatment.
3. **Mantle Cell Lymphoma (MCL)**: Patients whose disease remains difficult to control even after multiple treatments, including BTK inhibitors.
4. Patients whose lymphoma is resistant to traditional treatments or who experience rapid relapse after therapies such as conventional chemotherapy and targeted treatments.
5. More indications include diffuse large B-cell lymphoma (not otherwise specified), DLBCL transformed from follicular lymphoma, primary mediastinal large B-cell lymphoma, and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement, as well as grade 3b follicular lymphoma.
CAR-T therapy offers new hope to these patients by targeting the CD19 antigen on the surface of tumor cells.
## Physical Condition: Stable Health is Key
While CAR-T therapy has shown significant efficacy, the potential for serious side effects, such as **cytokine release syndrome (CRS)** and **neurotoxicity**, means that patients must be in stable health to tolerate the risks associated with treatment. Suitable patients should meet the following conditions:
– **Good heart and lung function**: The patient’s cardiovascular and respiratory health should be adequate to handle the stress of treatment.
– **Normal liver and kidney function**: Liver enzymes (such as ALT) and creatinine levels should be within normal ranges to ensure that the patient can properly eliminate toxins from the body.
– **Stable immune system**: Patients should not have severe infections or immunosuppressed conditions, as CAR-T therapy can further weaken the immune system, increasing the risk of infection.
Additionally, patients need to achieve a performance status score of 0-1 on the ECOG scale, indicating that they have good functional ability and can handle daily activities independently.
## Pre-Treatment Testing: Ensuring Proper Antigen Expression
CAR-T therapy targets specific antigens (such as CD19) on the surface of tumor cells, so patients’ cancer cells must express these antigens for treatment to be effective. If tests show that the tumor cells do not express the relevant antigens, CAR-T therapy will not work effectively.
## Costs and Resources: The Advantages of CAR-T in China
Compared to Western countries, CAR-T therapy in China is relatively affordable, usually costing between hundreds of thousands to one million RMB, whereas in the U.S., CAR-T treatment can cost several hundred thousand dollars. For patients with the financial ability but who find it difficult to bear the high costs of treatment in the West, China offers a significant cost advantage.
Moreover, China boasts several top-tier hospitals with established CAR-T treatment programs, such as leading cancer centers in Beijing, Shanghai, and Guangzhou. These hospitals have extensive clinical experience, offering international patients convenient access to treatment.
## Contact Us:
The Advanced Medicine in China team has a wealth of connections with doctors and hospitals, enabling us to quickly help you find the most suitable hospital and expert team for your specific needs. In China, we provide a fast-track option for CAR-T treatment.
## Conclusion
With its cost advantages, advanced medical resources, and broad indications, CAR-T therapy in China has attracted a large number of international lymphoma patients. For those who have failed traditional treatments, are in good physical condition, and have sufficient financial means, CAR-T treatment in China is an ideal choice. If you or someone close to you meets these conditions, consider coming to China for world-leading CAR-T therapy, and open the door to new hope in the fight against cancer.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTherapy #CARTinChina #RelapsedLymphoma #RefractoryLymphoma #FollicularLymphoma #MantleCellLymphoma #Immunotherapy #CancerRevolution #AdvancedCancerCare #CD19Targeting #CancerHope #CancerCare #ChineseHospitals #GlobalHealth #CancerSurvivors #CARTSuccess #MedicalInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Chinese CAR-T cell clinical and therapeutic have entered a period of rapid growth!
**Chinese CAR-T cell clinical and therapeutic have entered a period of rapid growth!**
Chinese CAR-T
According to the American clinical trial database Clinicaltrials, as of November 10, 2023, China has taken the lead in CAR-T cell therapy clinical research with a total of 655 studies, marking the country’s first foray into the international forefront of a new drug development field. Among them, Legend Biotech’s SicajioLunsei and Koji Pharmaceutical’s Claudin18.2 CAR-T have both achieved global leadership. Additionally, several companies are also advancing next-generation CAR-T and allogeneic CAR-T technologies, showing promising initial data and potential for global market success.
CAR-T therapy
In terms of pricing, all three Chinese CAR-T therapies cost less than 1.3 million RMB (approximately 180,000 USD), only one-third of Novartis’s Kymriah. Specifically, JW Therapeutics’ Beinoda (Relmacabtagene autoleucel) is priced at 1.29 million RMB, FOSUNKITE’s Yikaida (Yescarta) is priced at 1.2 million RMB, and IASO’s Fukesu (Equecabtagene ciloleucel) is priced at 1.166 million RMB. Furthermore, Juventas, a domestic Chinese CAR-T product developed by Hegen Biotech, has set a new milestone in the pricing of Chinese CAR-T therapy, priced at 999,000 RMB per dose (less than 140,000 USD).
The year 2021 marked the beginning of cellular immunotherapy in China, with CAR-T therapy leading the way as one of the future development directions. CAR-T therapy primarily involves modifying T cells to recognize specific targets on tumor cells. Theoretically, there could be countless CAR-T therapies targeting different targets, which means endless possibilities.
We hope that in the near future, with the efforts of medical researchers both domestically and internationally, we can reduce the side effects of cell therapy, lower prices, and break through the bottleneck of solid tumors, benefiting more and more late-stage cancer patients!